Sponsored by the Asper Foundation and Reichman University
Israeli digital microscopy company Scopio Lab announced on Wednesday the commercial launch of its FDA-cleared, CE-approved Full-Field Peripheral Blood Smear (FF-PBS) application on the X100 platform.
The company said the commercialization of this application is an “important step” in the firm’s plan to “transform hematology and introduce a new line of digital solutions for cell morphology analysis that enables earlier detection, diagnosis, and treatment for improved patient outcomes.
The company’s FF-PBS system is an all-in-one automated in-vitro hematology diagnostic platform that enables remote consultation and includes a computer-vision-based decision support system.
It is said to be the first end-to-end digital solution on the market that offers full-field imaging and an AI-powered Decision Support System (DSS) with true remote capabilities to optimize the blood smear analysis process.
The imaging platform uses computational photography to provide unprecedented images of vast numbers of cells. Lab practitioners have a full-field view on the slide at 100X magnification, including the feathered edge. That means that lab teams and hematopathologists can see the scan in full context or zoom in on the smallest details.
Founded in 2015, Scopio Labs’ platform automates the imaging of full microscopy samples into unique high-resolution digital scans using state-of-the-art computation photography techniques. The company has also built and integrated various AI and remote consultation solutions for large and small labs and hospitals to improve diagnostic processes and reduce turnaround time.
Earlier this year, the company launched ScopioVet, an end-to-end digital cytology solution for veterinary professionals. Last April, Scopio Labs raised $16 million in a Series B funding round led by Tel Aviv-based firm Olive Tree Ventures.
“Surprisingly, the healthcare industry still depends on inefficient solutions for blood smear analysis having to choose between manual review on the microscope or solutions that only offer a partial view to base diagnoses on,” said Itai Hayut, CEO of Scopio Labs. “Our digital approach overcomes the tradeoff between resolution and field of view, allowing labs to analyze all relevant regions on a blood scan at an unprecedented resolution while maintaining full-field context – without necessitating manual counting. This gives labs and clinicians a complete picture for each case, which combined with our AI-driven decision support system ensures they can work more efficiently and never have to go back for a manual review of the sample.”